Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Equity Ratio (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Equity Ratio for 16 consecutive years, with 0.38 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 19.45% to 0.38 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.38 through Dec 2025, up 19.45% year-over-year, with the annual reading at 0.38 for FY2025, 19.45% up from the prior year.
  • Equity Ratio hit 0.38 in Q4 2025 for Ani Pharmaceuticals, up from 0.36 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.58 in Q2 2024 to a low of 0.02 in Q3 2024.
  • Historically, Equity Ratio has averaged 0.17 across 5 years, with a median of 0.0 in 2023.
  • Biggest YoY gain for Equity Ratio was 14211884.6% in 2024; the steepest drop was 716315.91% in 2024.
  • Year by year, Equity Ratio stood at 0.0 in 2021, then skyrocketed by 100.03% to 0.0 in 2022, then soared by 68.08% to 0.0 in 2023, then skyrocketed by 14211884.6% to 0.31 in 2024, then increased by 19.45% to 0.38 in 2025.
  • Business Quant data shows Equity Ratio for ANIP at 0.38 in Q4 2025, 0.36 in Q3 2025, and 0.0 in Q2 2025.